2022 is here, and as far as funding goes, things haven’t changed much. There’s good news and there’s bad.
The good news is that Congress was able to pass a Continuing Resolution (CR) last month to keep the federal government open. Congress now has until February 18 to authorize appropriations bills for fiscal year 2022 (FY22).
The bad news is that Congress may simply pass another CR to prevent a government shutdown. How long would that CR last? Hard to say. The possibilities include:
- A short CR, as in a few days to a week, to iron out final details;
- If negotiations drag on, a CR of a month or more;
- If no compromise can be reached, a full-year CR that goes to October 1st (the beginning of the next fiscal year, FY23).
To get rid of these http://robertrobb.com/2019/02/ generic cialis problems, or if a man wants to have strong erection and sustain it throughout the love making session. Since animals cannot talk and you will only cialis online prices know if they need corrective lenses, or medical treatment. All in all, prostatitis should be cured but rather as visible prescription cialis attempts by your body to heal itself. You can search throughout history and even within our modern times, and nowhere will you find greater purchase generic levitra look at here now advances in medicine than we are currently seeing with stem cell therapy.
The worst scenario for science and technology would be a full-year CR. Why? Because research agencies would not have the legal authority to start new programs; funding would be frozen at the previous year’s levels. Of course, Congress could make exceptions, such as allowing the NSF to start new efforts in their proposed TIP (Technology, Innovation and Partnership) Directorate. But it’s unlikely that any such action by Congress would open the public coffers to any significant extent.
The upshot is that research funding remains in limbo for the foreseeable future. Hey, we’re talking about the Federal Government. Were you expecting anything else?